We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Check Point Software Technologies
CHKP
$12.8B
| $3.81M | 0.01% |
34,354
-4,017
| -10% | -$451K |
|
1427
Dolby
DLB
$5.75B
| $3.8M | 0.01% |
55,237
+423
| +0.8% | +$28K |
|
1428
Abercrombie & Fitch
ANF
$4.86B
| $3.8M | 0.01% |
219,616
+7,615
| +4% | +$126K |
|
|
SMAR
1429
DELISTED
Smartsheet Inc.
SMAR
| $3.8M | 0.01% |
84,527
+3,001
| +4% | +$124K |
|
1430
The Greenbrier Companies
GBX
$1.54B
| $3.79M | 0.01% |
116,964
+6,785
| +6% | +$203K |
|
1431
Standard Motor Products
SMP
$881M
| $3.79M | 0.01% |
71,250
+3,859
| +6% | +$197K |
|
1432
Ingersoll Rand
IR
$34.9B
| $3.79M | 0.01% |
103,225
+1,134
| +1% | +$37.2K |
|
|
TMHC
1433
DELISTED
Taylor Morrison
TMHC
| $3.78M | 0.01% |
172,948
+1,786
| +1% | +$42.9K |
|
|
P
1434
Everpure Inc
P
$27.8B
| $3.76M | 0.01% |
219,804
+3,909
| +2% | +$69.1K |
|
1435
Envista
NVST
$4.66B
| $3.75M | 0.01% |
+126,664
| New | +$3.6M |
|
|
SAGE
1436
DELISTED
Sage Therapeutics
SAGE
| $3.75M | 0.01% |
51,940
+1,172
| +2% | +$144K |
|
1437
Southern Copper
SCCO
$164B
| $3.74M | 0.01% |
95,062
-4,640
| -5% | -$162K |
|
1438
Greif
GEF
$5.12B
| $3.74M | 0.01% |
84,582
-947
| -1% | -$39.2K |
|
1439
Moderna
MRNA
$22.5B
| $3.74M | 0.01% |
191,035
+20,837
| +12% | +$370K |
|
1440
Simply Good Foods
SMPL
$989M
| $3.72M | 0.01% |
130,497
+19,271
| +17% | +$508K |
|
1441
Rapid7
RPD
$726M
| $3.72M | 0.01% |
66,362
+3,435
| +5% | +$179K |
|
|
VGR
1442
DELISTED
Vector Group Ltd.
VGR
| $3.71M | 0.01% |
390,153
+31,810
| +9% | +$278K |
|
|
CIT
1443
DELISTED
CIT Group Inc.
CIT
| $3.71M | 0.01% |
81,202
-15,364
| -16% | -$688K |
|
|
XLRN
1444
DELISTED
Acceleron Pharma
XLRN
| $3.69M | 0.01% |
69,536
+2,300
| +3% | +$105K |
|
|
HOUS
1445
DELISTED
Anywhere Real Estate
HOUS
| $3.67M | 0.01% |
379,042
+26,236
| +7% | +$241K |
|
1446
Buckle
BKE
$2.34B
| $3.65M | 0.01% |
135,116
+6,481
| +5% | +$154K |
|
1447
Chord Energy
CHRD
$7.32B
| $3.65M | 0.01% |
1,118,733
+41,954
| +4% | +$120K |
|
|
DMC
1448
Del Monte Corp
DMC
$1.4B
| $3.65M | 0.01% |
104,238
+4,900
| +5% | +$157K |
|
1449
Regenxbio
RGNX
$672M
| $3.64M | 0.01% |
88,934
+9,452
| +12% | +$373K |
|
1450
ePlus
PLUS
$2.47B
| $3.62M | 0.01% |
85,886
+4,572
| +6% | +$186K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.